DEVONIAN HEALTH GROUP INC (GSD.CA) Stock Price, Forecast & Analysis
Canada - TSX-V:GSD - CA2518348008 - Common Stock
GSD.CA Key Statistics, Chart & Performance
The current stock price of GSD.CA is 0.17 CAD. In the past year, price decreased by -32%.
GSD.CA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| BHC.CA | BAUSCH HEALTH COS INC | 1.85 | 3.65B | ||
| TLRY.CA | TILRAY BRANDS INC | N/A | 2.11B | ||
| CRON.CA | CRONOS GROUP INC | 50.43 | 1.35B | ||
| DHT-UN.CA | DRI HEALTHCARE TRUST | 7.44 | 882.49M | ||
| WEED.CA | CANOPY GROWTH CORP | N/A | 585.17M | ||
| GUD.CA | KNIGHT THERAPEUTICS INC | N/A | 582.13M | ||
| ACB.CA | AURORA CANNABIS INC | N/A | 391.50M | ||
| HITI.CA | HIGH TIDE INC | N/A | 382.07M | ||
| CPH.CA | CIPHER PHARMACEUTICALS INC | 23.13 | 374.74M | ||
| TSND.CA | TERRASCEND CORP | N/A | 366.04M | ||
| OGI.CA | ORGANIGRAM GLOBAL INC | N/A | 304.93M | ||
| NGEN.CA | NERVGEN PHARMA CORP | N/A | 255.47M |
Related stock screener links
About GSD.CA
Company Profile
Devonian Health Group, Inc. is a pharmaceutical company, which engages in the development of botanical drugs. The company is headquartered in Montmagny, Quebec and currently employs 6 full-time employees. The company went IPO on 2014-09-09. The company specializes in the development of drugs for various autoimmune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. The company is developing prescription drugs for the treatment of inflammatory autoimmune diseases, including but not limited to, ulcerative colitis and atopic dermatitis. The company is also involved in the development of cosmeceutical products, leveraging the same proprietary approach employed with their pharmaceutical offerings. Its flagship product, Thykamine, is a pharmaceutical product issued from its SUPREX platform, for the prevention and treatment of health problems related to inflammation and oxidative stress, including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune diseases. Its cosmeceutical products include R-Spinasome and Purgenesis. Its subsidiary, Altius Healthcare Inc., sells prescription pharmaceutical products.
Company Info
DEVONIAN HEALTH GROUP INC
360 rue des Entrepreneurs
Montmagny QUEBEC G5V 4T1 CA
CEO: Andre P. Boulet
Employees: 7
Phone: 15142487509
DEVONIAN HEALTH GROUP INC / GSD.CA FAQ
What does GSD do?
Devonian Health Group, Inc. is a pharmaceutical company, which engages in the development of botanical drugs. The company is headquartered in Montmagny, Quebec and currently employs 6 full-time employees. The company went IPO on 2014-09-09. The company specializes in the development of drugs for various autoimmune inflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. The company is developing prescription drugs for the treatment of inflammatory autoimmune diseases, including but not limited to, ulcerative colitis and atopic dermatitis. The company is also involved in the development of cosmeceutical products, leveraging the same proprietary approach employed with their pharmaceutical offerings. Its flagship product, Thykamine, is a pharmaceutical product issued from its SUPREX platform, for the prevention and treatment of health problems related to inflammation and oxidative stress, including ulcerative colitis, atopic dermatitis, psoriasis, rheumatoid arthritis, and other autoimmune diseases. Its cosmeceutical products include R-Spinasome and Purgenesis. Its subsidiary, Altius Healthcare Inc., sells prescription pharmaceutical products.
What is the current price of GSD stock?
The current stock price of GSD.CA is 0.17 CAD. The price increased by 13.33% in the last trading session.
What is the dividend status of DEVONIAN HEALTH GROUP INC?
GSD.CA does not pay a dividend.
How is the ChartMill rating for DEVONIAN HEALTH GROUP INC?
GSD.CA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
Can you provide the sector and industry classification for DEVONIAN HEALTH GROUP INC?
DEVONIAN HEALTH GROUP INC (GSD.CA) operates in the Health Care sector and the Pharmaceuticals industry.
Can you provide the market cap for DEVONIAN HEALTH GROUP INC?
DEVONIAN HEALTH GROUP INC (GSD.CA) has a market capitalization of 27.88M CAD. This makes GSD.CA a Nano Cap stock.
GSD.CA Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to GSD.CA. When comparing the yearly performance of all stocks, GSD.CA is a bad performer in the overall market: 87.55% of all stocks are doing better.
GSD.CA Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to GSD.CA. The financial health of GSD.CA is average, but there are quite some concerns on its profitability.
GSD.CA Financial Highlights
Over the last trailing twelve months GSD.CA reported a non-GAAP Earnings per Share(EPS) of -0.03. The EPS decreased by -60.37% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -22.47% | ||
| ROE | -58.41% | ||
| Debt/Equity | 0.01 |